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Mesenchymal stem/stromal cells (MSCs) can either
suppress or promote tumors. We found previously
that incubation of human bone marrow MSCs
(hMSCs) with TNF-a upregulated multiple genes
including TRAIL, which has cancer apoptotic activity.
Here, we show that weekly infusions into mice of
hMSCs preactivated with TNF-a inhibited the pro-
gression of lung tumors formed from MDA-MB-231
breast cancer cells (MDA). In coculture, preactivated
hMSCs induced apoptosis in MDA and several other
TRAIL-sensitive cancer cell lines. TRAIL was further
upregulated by apoptotic MDA cells in a TLR3-
dependent manner; this feedforward cycle increased
MDA cell apoptosis, and the chemotherapeutic drug
doxorubicin had a synergistic effect. Also, activated
hMSCs secreted DKK3 to suppressMDA cell cycling,
leading to a decrease in b-catenin and cyclin D1/D3
and an increase in p21. Thus, culturing hMSCs with
TNF-a enhances their tumor-suppressive properties
and may represent a useful strategy to develop
hMSC-basedapproaches for the treatmentof cancer.
INTRODUCTION
Nonhematopoietic progenitor cells derived from bone marrow,
known as mesenchymal stem cells or multipotent stromal cells
(MSCs), have been investigated for the treatment of cancers
because they are able to preferentially home to tumors and
incorporate into tumor stroma (Kanehira et al., 2007; Kucerova
et al., 2007; Studeny et al., 2004; Xin et al., 2007), but previous
research has yielded conflicting results. Some reports showed
that MSCs inhibited tumor growth (Djouad et al., 2006; Kidd
et al., 2010; Tian et al., 2010; Zhu et al., 2009), but others that
the MSCs promoted tumor growth or metastases (Djouad
et al., 2003; Karnoub et al., 2007; Kurtova et al., 2009; Patel
et al., 2010). Recently, we observed that incubation of human
MSCs (hMSCs) with recombinant human tumor necrosis
factor-a (TNF-a) activated the cells to express a number of
potentially therapeutic proteins including tumor necrosis
factor-a-related apoptosis-inducing ligand (TRAIL) (Rahman
et al., 2009). TRAIL causes apoptosis in many malignant cells
but not in normal cells; for this reason, soluble recombinant
TRAIL was employed in a series of clinical trials (Gazitt, 1999;CellJohnstone et al., 2008; Kelley et al., 2001), but the success
was limited by the short half-life in serum (Kelley et al., 2001)
and the lower bioactivity of the soluble protein compared to
the membrane-bound form (Rus et al., 2005). One strategy to
overcome the limitations of soluble TRAIL is to use hMSCs as
delivery vectors and thereby capitalize on their ability to home
to tumors. hMSCs that were transduced with viral vectors to
overexpress TRAIL suppressed tumor xenografts in several
in vivo models including glioma, colorectal carcinoma, and
metastatic breast cancer (Grisendi et al., 2010; Loebinger
et al., 2009; Menon et al., 2009; Mohr et al., 2008; Mueller
et al., 2011). The use of viral vectors, however, introduces limita-
tions such as insertional mutagenesis and phenotypic changes
in the hMSCs.
We also observed that DKK3 expression was increased upon
exposure of hMSCs to TNF-a. DKK3 is suppressed in many
breast cancer cell lines because the gene promoter is hyperme-
thylated (Kuphal et al., 2006), an observation suggesting that
DKK3 is a tumor suppressor gene. Furthermore, several reports
showed that epigenetic inactivation of DKK3 stimulates the
Wnt/b-catenin pathway that plays an important role in tumori-
genesis (Bafico et al., 2004; Clevers, 2006; Vogelstein and
Kinzler, 2004). This inactivation promotes the growth of human
breast, lung, and cervical cancer (Lee et al., 2009a; Veeck
et al., 2008; Yue et al., 2008).
Because hMSCs activated with TNF-a expressed both TRAIL
and DKK3, we tested the hypothesis that activated hMSCs are
tumor suppressive. Here, we show that preactivated hMSCs
reduced the tumor burden in a lung metastatic xenograft
model that was produced with MDA-MB-231 (MDA) in vivo.
They also induced apoptosis of MDA cells and several other
TRAIL-sensitive cancer cell lines and prevented cell-cycle pro-
gression of MDA cells in vitro.RESULTS
Intravenous Infusions of hMSCs Preactivated
with TNF-a Reduced the Size of Tumors
in a Xenograft Mouse Model
First, we observed that expression of TRAIL and DKK3 protein
was upregulated in hMSCs after incubating the cells with
10 ng/ml TNF-a (Figure 1A and Figures S1A and 1B, available
online). To explore whether hMSCs preactivated with TNF-a
(preactivated hMSCs) have the ability to induce cell death in
cancer cells, a xenograft model of human breast cancer metas-
tasis with progressive tumor growth (Figure S1B) was induced
by injecting MDA cells (2 3 106) intravenously into NOD/SCIDStem Cell 11, 825–835, December 7, 2012 ª2012 Elsevier Inc. 825
Figure 1. IV Infusions of hMSCs Preactivated
with TNF-a Reduced Tumors in a Xenograft
Mouse Model
(A) Western blot assay for TRAIL in hMSCs pre-
activated by incubation with TNF-a for 24 or 48 hr in
2% CM.
(B) ELISA assay for DKK3 in medium from hMSCs
incubated as in (A) for 24 hr. Values are means ± SD
(n = 3; *p < 0.05; two-tailed Student’s t test).
(C) Schematic diagram.
(D) Real-time PCR for human Alu sequences in
mouse lungs. Values are means ± SD for HBSS (n =
10, week 6; n = 7, week 11); for hMSCs (n = 10, week
6; n = 8, week 11) and for preactivated hMSCs (n =
10, week 6; n = 9, week 11); *p < 0.05 and **p < 0.01;
Kruskal-Wallis test).
(E) Representative gross images of mouse lungs
from mice treated for 11 weeks. The black arrows
indicate tumor nodules.
(F) Representative histology images (H&E staining)
of lung sections from mice treated for 11 weeks.
See also Figure S1.
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Preactivated hMSCs Exert Tumor-Suppressive Effectsmice (Figure 1C). The model was previously shown to respond
to hMSCs virally transduced to express TRAIL (Loebinger
et al., 2009). A week after MDA injection, either male control
hMSCs (2 3 106) or male preactivated hMSCs (2 3 106) were
intravenously injected weekly for 4 or 9 consecutive weeks.
Both preactivated hMSCs and control hMSCs were found by
immunofluorescence (IF) staining in the tumors 1 day after IV
injection (Figure S1C). Some of the cells migrated to tumor sites
and incorporated into the tumors (Figure S1C). However, the
cells did not persist; after 1 week, less than 0.01% of the infused826 Cell Stem Cell 11, 825–835, December 7, 2012 ª2012 Elsevier Inc.cells were detected by qPCR for the
human Y chromosome in the injected
male hMSCs (not shown). Therefore, we
were able to employ qPCR for repetitive
human Alu sequences to provide quanti-
tative estimates of the growth of the
human female breast cancer cells in
the mouse lung. We did not examine the
distribution of cancer cells and hMSCs
in other organs. The results demonstrated
that preactivated hMSCs suppressed
tumor cell growth compared to HBSS
control group at both early and late time
points (Figure 1D). Controls of hMSCs
that were not exposed to TNF-a and
that did not express TRAIL (Figure 1A
and S1A) did not have any statistically
significant effect on tumor burden com-
pared to the HBSS control group (Fig-
ure 1D). The gross pictures and histology
images (H&E staining) of lungs demon-
strated that injection of preactivated
hMSCs decreased the number of tumor
nodules (Figures 1E and 1F). The decrease
in tumor burden seemed larger by gross
images and histology of the lung (Figures
1E and 1F) than by the assays for Alusequence (Figure 1D), perhaps because the assays for Alu
sequences underestimated the tumor burden in the control
samples as a result of necrosis and DNA degradation at the
center of large tumors. Therefore, the results suggested that
the hMSCs suppressed the tumors by homing to the tumor site.
hMSCs Induced TRAIL-Dependent Apoptosis
in MDA Cells
To determine whether hMSCs can induce apoptosis in MDA
cells in vitro, MDA cells were directly cocultured with hMSCs,
Figure 2. hMSCs Induced TRAIL-Depen-
dent Cell Death in MDA Cells
(A) After coculture of MDA (105) with equal number
of activated hMSCs for 24 hr, cells were collected
and labeled with anti-CD90 antibody to distinguish
hMSCs from MDA.
(B) Apoptosis was assayed by staining Annexin
V-FITC & 7AAD in MDA cells identified as CD90-
negative cells from Figure 2A.
(C) Number of live MDA cells from coculture.
Values are means ± SD for cell counting (n = 4;
**p < 0.01; one-way ANOVA).
(D) Live cancer cell numbers as percent of control
following 24 hr coculture with TNF-a, hMSCs, or
activated hMSCs. Values are means ± SD for cell
counting (n = 3 or 4; **p < 0.01; N.S., not signifi-
cant; one-way ANOVA).
(E) Percentage of MDA cell death following 24 hr
coculture with preactivated hMSCs and with IgG
control antibody or anti-TRAIL antibody. Values
are means ± SD for cell counting (n = 4; **p < 0.01;
two-tailed Student’s t test).
(F) Annexin V-FITC & 7AAD staining in MDA cells
from experiment as in (E).
(G) Number of live MDA cells following 24 hr
coculture with activated hMSCs and Troglitazone
(TGZ). Values are means ± SD for cell counting
(n = 4; *p < 0.05; **p < 0.01; one-way ANOVA).
See also Figure S2.
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activated hMSCs. After 24 hr coculture, hMSCs and MDA cells
were distinguished by antibodies to CD90, an epitope expressed
by hMSCs but not by MDA cells (Figure 2A), and apoptosis of
MDA cells was analyzed using 7AAD and Annexin V staining
(Figure 2B). When MDA cells were cultured with activated
hMSCs or preactivated hMSCs, the apoptosis increased
remarkably with a corresponding decrease in the number of
live MDA cells (Figure 2C). Naive hMSCs cocultured with MDA
cells also reduced the number of live MDA cells, but to a lesser
extent than activated hMSCs (Figure 2C). In addition, TRAIL
expression in hMSCs was induced by incubation of the cells
with two other proinflammatory agents, LPS and IFN-g (Figures
S2A and S2B). hMSCs preincubated with LPS or IFN-g induced
apoptosis of MDA cells in cocultures (Figures S2C and S2D).
However, preactivated hMSCswith LPS inducedmore cell deathCell Stem Cell 11, 825–835,because the upregulation of TRAIL by
LPS was 500-fold whereas the upregula-
tion by IFN-g was only 30-fold. We also
cocultured activated hMSCs with other
TRAIL-sensitive cancer cell lines (Fig-
ure 2D). The activated hMSCswere effec-
tive in reducing the live cell number in two
triple-negative breast cancer (TNBC) cell
lines (HCC38 and MDA-MB-436) in addi-
tion to MDA, a pancreatic cancer cell line
(CFPAC), a cervical cancer cell line
(HeLa), and carcinomic human alveolar
basal epithelial cells (A549). Activated
hMSCs had no effect on a line of glioblas-
toma cells (U87) even though MSCstransduced to express TRAIL were previously shown to inhibit
intracranial U87 glioma growth (Menon et al., 2009). The discrep-
ancy is probably explained by the observation that U87 cells are
less sensitive to rhTRAIL thanMDA cells (Figure S2E). The results
suggest that preconditioning hMSCs to express TRAIL can be
useful, but gene modification may be necessary to obtain
optimal therapeutic benefits in some circumstances.
We elected to focus on the three triple-negative breast
cancer cell lines. Induction of apoptosis by hMSCs in all three
cell lines was partially reduced when TRAIL activity was
inhibited by a TRAIL blocking antibody: MDA-MB-231 (denoted
as MDA in Figures 2E and 2F), HCC38, and MDA-MB-436 cells
(Figure S2F). The antibody was more effective in blocking the
effects of rhTRAIL than in blocking the effects of preactivated
hMSCs (Figures 2E and 2F), apparently because the hMSCs
were continually activated to express TRAIL in the cocultureDecember 7, 2012 ª2012 Elsevier Inc. 827
Figure 3. Conditions for Coculture with
MDA and hMSCs and Variations among
hMSC Preparations
Cells were cultured for 24 or 48 hr as in Figure 2.
(A) Effect of TNF-a concentration on live MDA cells
recovered from 48 hr cocultures. Values are
means ± SD for cell counting (n = 4;*p < 0.05 and
**p < 0.01; one-way ANOVA).
(B) Lack of effect in transwell cocultures for 24 hr.
Values are means ± SD for cell counting (n = 4;
**p < 0.01; two-tailed Student’s test).
(C) Decrease in live MDA cells recovered from
cocultures with increasing ratio of hMSCs toMDA.
Values are means ± SD for cell counting (n = 4;
*p < 0.05; N.S., not significant; one-way ANOVA).
(D) Variations in recovery of live MDA cells from
cocultures with preactivated MSCs from different
donors. Values are means ± SD (n = 3).
(E) Variations in TRAIL expression in preactivated
hMSCs from different donors. Values are means ±
SD for triplicates of the assay.
(F) Decrease in TRAIL expression in preactivated
hMSCs after expansion in culture through 25
population doublings (PD). Values are means ± SD
for triplicates of the assay.
(G) Decrease in effectiveness in cocultures of
preactivated hMSCs expanded through 25 pop-
ulation doublings. Values are means ± SD for cell
counting (n = 4; **p < 0.01; two-tailed Student’s
t test).
(H) Decrease in recovery of live MDA cells from
cocultures after preincubation of the MDA cells for
24 hr with doxorubicin (Dox; 100 ng/ml).
(I) Percentage of live MDA cell growth from
experiment as in (H). Values are expressed as
means ± SD (n = 4; **p < 0.01; N.S., not significant;
one-way ANOVA).
See also Figure S3.
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Preactivated hMSCs Exert Tumor-Suppressive Effectssystem. Also, inhibition of a decoy receptor for TRAIL (osteopro-
tegerin; OPG) in hMSCs with troglitazone (Krause et al., 2010)
increased the apoptosis compared to control (Figure 2G). The
results indicated that activated hMSCs induced TRAIL-
dependent apoptosis in the three triple-negative breast cancer
cell lines.
Conditions for Activation of hMSCs by TNF-a
and Variations among hMSC Preparations
The activation of hMSCs by TNF-a to induce apoptosis of MDA
cells in coculture was concentration dependent over the range
of 0.1 to 10 ng/ml (Figure 3A). Activation of hMSCs with as little
as 0.1 ng/ml TNF-a was adequate to induce MDA apoptosis.
Cell-to-cell contact was required, since the hMSCs had no effect
in transwell cocultures (Figure 3B) and an increase in soluble
TRAIL was not detected in conditioned medium from the cells
(Figure S3A), suggesting that TRAIL expressed by hMSCs was828 Cell Stem Cell 11, 825–835, December 7, 2012 ª2012 Elsevier Inc.transmembrane. The apoptosis of MDA
cells in cocultures increased with in-
creasing ratios of hMSCs to MDA cells
over the range of 0.06:1 to 2:1 (Figure 3C).
Control experiments demonstrated that
human foreskin fibroblasts (Hs68) didnot express TRAIL upon incubation with TNF-a (Figure S3B)
and they did not induce apoptosis of MDA cells upon coculture
(Figure S3C). Two other samples of primary preparations of
human dermal fibroblasts (hDF) slightly decreased the number
of live MDA cells when cocultured with the MDA cells (Figures
S3D and S3E) and TNF-a, but the effect was not inhibited by
a blocking antibody to TRAIL (Figure S3F).
As reported previously, there were variations in the quality
of hMSCs obtained from bone marrow aspirates, even if the
aspirates were drawn from the same normal volunteer at the
same session and the hMSCs were isolated and expanded
with a standardized protocol (Phinney et al., 1999; Sekiya
et al., 2002; Wolfe et al., 2008). Therefore, we compared four
preparations of hMSCs, identified by their anonymous donor
numbers. The four samples of preactivated hMSCs demon-
strated large variations in the apoptosis induced in theMDA cells
(Figure 3D). As expected, the apoptosis induced by the hMSCs
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Preactivated hMSCs Exert Tumor-Suppressive Effectscorrelated with their levels of TRAIL expression following incuba-
tion with TNF-a (Figure 3E).
As observed previously, cultures of hMSCs lose many of their
biological properties as they are expanded beyond about 20
population doublings in culture (Digirolamo et al., 1999; Larson
et al., 2010). As expected, hMSCs gradually lost their ability to
express TRAIL upon TNF-a activation (Figure 3F) and to induce
apoptosis of MDA cells as they were expanded through 20 or
25 population doublings (Figure 3G). These observations
demonstrated that apoptosis induced by TNF-a activated
hMSCs required upregulation of TRAIL and that the effective-
ness of the cells varies with the quality of the hMSCs.
hMSCs Acted Synergistically with Doxorubicin
in Suppressing MDA Cells
To examine synergistic interactions between TRAIL-expressing
activated hMSCs and chemotherapeutic drugs, we treated
MDA cells with both doxorubicin and hMSCs or activated
hMSCs. As reported previously (Mallory et al., 2005), doxoru-
bicin in a low concentration of 100 ng/ml (0.2 mM) suppressed
proliferation of MDA as indicated by the decrease in recovery
of live cells (Figure 3I) but did not induce apoptosis (Figure 3H).
Incubation of MDA cells with doxorubicin decreased the number
of live MDA cells recovered from cultures after 24 hr (Figure 3I)
in a dose-dependent manner (Figure S3G). Addition of hMSCs,
however, together with 100 ng/ml doxorubicin both further
decreased the number of live MDA cells recovered from the
cultures (Figure 3I) and greatly increased apoptosis (Figure 3H).
The effect was synergistic in that the decrease in live MDA cells
was greater than the additive effect observed with doxorubicin
alone (Figure 3H) and activated hMSCs alone (Figure 2B). Of
special note, the hMSCs were effective regardless of TNF-a
activation (Figures 3H and 3I). Since doxorubicin enhances
TRAIL-induced apoptosis by activating caspase or TRAIL recep-
tors on cancer cells (Buchsbaum et al., 2003; Keane et al., 1999;
Singh et al., 2003), the low level of TRAIL activation in hMSCs,
which was induced by the coculture with MDA even without
TNF-a (Figure S3H), might be sufficient to induce the apoptosis
in MDA cells, and then these dead cells create feedforward stim-
ulation of TRAIL. This synergistic effect was replicated in two
additional triple-negative breast cancer cell lines HCC38 and
MDA-MB-436 (Figure S3I). Therefore, combination treatment of
a chemotherapeutic drug and activated hMSCs can create
synergistic effects and preactivation of hMSCs with proinflam-
matory cytokines may not be essential to induce apoptosis in
MDA cells exposed to doxorubicin.
Expression of TRAIL on hMSCs was Markedly Increased
upon Coculture
Apoptosis of MDA cells by activated hMSCs appeared to
increase with time in culture (Figure 4A). Therefore, we assayed
the levels of TRAIL in hMSCs isolated from the cocultures. There
was a 10-fold increase in the expression of TRAIL in hMSCs
recovered from cocultures of MDA cells and activated hMSCs
(Figures 4B and 4C). The results suggested the hypothesis
that apoptotic MDA cells might enhance expression of TRAIL
in hMSCs.
To test the hypothesis, we incubated hMSCs with apoptotic
MDA cells. The apoptotic MDA cells were prepared by incuba-Celltion with 100 ng/ml of recombinant human TRAIL (rhTRAIL) for
24 hr in serum-free media (Figure S4A) and recovery of nonad-
herent cells from the cultures. As expected, apoptotic MDA cells
enhanced TRAIL expression in TNF-a activated hMSCs to the
same extent as in the coculture system (compare Figure 4D to
4B). We then tested the hypothesis that the effects of the
apoptotic MDA cells were explained by RNA that is released
from damaged tissue (Kariko´ et al., 2004). We assayed hMSCs
for expression of TLR3, a specific receptor for RNA (Kariko´
et al., 2004) that increases NF-kB signaling and thereby triggers
an essential step in the pathway for induction of TRAIL (Rivera-
Walsh et al., 2001). Expression of TLR3 in hMSCs was increased
by incubation with TNF-a and further enhanced by coculture of
the activated hMSCs with MDA cells (Figures 4E). Increased
expression of TLR3 was also observed when hMSCs were
treated with apoptotic MDA cells (Figure 4F). Treatment of
apoptotic MDA cells with RNase inhibited the increase of TRAIL
in hMSCs (Figure 4G). Treatment with DNase also inhibited the
increase of TRAIL in hMSCs; however, the expression level of
TLR9, a receptor for DNA (Zhang et al., 2010), was low in hMSCs
and was not upregulated by treatment of TNF-a or apoptotic
MDA cells (data not shown). The roles of RNA and TLR3 were
confirmed by the observations that poly(I:C), a synthetic ligand
for TLR3 (Alexopoulou et al., 2001), increased expression of
TRAIL in hMSCs (Figures 4H and S4B) and caused a small but
statistically significant increase in MDA apoptosis when added
to cocultures (Figure 4I). Furthermore, adding a TLR3 blocking
antibody reduced apoptosis of MDA cells in the coculture
system and led to recovery of greater numbers of live MDA cells
(Figure 4J and S4C). The results suggested that the further
increase of TRAIL in hMSCs observed in cocultures with MDA
cells was mediated by feedforward stimulation of TLR3 by
RNA, by DNA, and probably by other DAMPs from apoptotic
MDA cells.
Activation of hMSCs with TNF-a Inhibited Cell-Cycle
Progression in MDA Cells
In the coculture system, preactivated hMSCs also inhibited cell-
cycle progression in the recovered adherent viable MDA cells
(Figures 5A and S5A). In transwell cocultures, the inhibition
was less: 3.3% increase in G1 (Figures S5B and S5C) versus
17.4% in cocultures with direct contact between the cells
(Figures 5A and S5A). The results therefore suggested that
cell-to-cell contact was involved.
As surrogate markers of cell-cycle arrest, expression of cyclin
D1, cyclin D3, and p21 was assayed. The MDA cells from cocul-
ture with activated hMSCs downregulated expression of cyclin
D1 and D3 (Figures 5B–5D) and upregulated p21 expression
(Figures 5E and 5F). TNF-a had no significant effect on the
expression of cyclin D1, D3 and p21 in MDA cells (Figures 5B–
5F). To test whether DKK3 upregulation in activated hMSCs
(Figures 1B and 6A–6C) inhibited the Wnt/b-catenin-mediated
cell-cycle progression in MDA cells (Tetsu and McCormick,
1999), we assessed b-catenin by IF staining (Figure 6D and
6E). In control MDA cells, b-catenin was present either as
discontinuous dot-like labeling in the cytoplasm or within the
nucleus. In cocultures, b-catenin was markedly decreased
(Figures 6D and 6E). In addition, addition of rhDKK3 decreased
the number of b-catenin-expressing MDA (Figures 6F and S6A)Stem Cell 11, 825–835, December 7, 2012 ª2012 Elsevier Inc. 829
Figure 4. Expression of TRAIL on hMSCs
Increased upon Coculture with MDA
(A) Live MDA cells following 48 hr coculture with
activated hMSCs or rhTRAIL (200 ng/ml).
(B) Real-time RT-PCR for TRAIL expression in
hMSCs (105) following 24 hr treatment of TNF-a or
coculture with MDA (105) and TNF-a. Values are
means ± SD for triplicates of the assay.
(C) Western blot analysis for TRAIL in hMSCs from
experiment in (B).
(D) Real-time RT-PCR for TRAIL in hMSCs
following 24 hr incubation with apoptotic MDA
cells (apotMDA) andwith or without TNF-a. Values
are means ± SD for triplicates of the assay.
(E) Real-time RT-PCR for TLR3 in hMSCs from
experiment as in (B). Values are means ± SD for
triplicates of the assay.
(F) Real-time RT-PCR for TLR3 in hMSCs from
experiment as in (D). Values are means ± SD for
triplicates of the assay.
(G) Real-time RT-PCR for TRAIL in hMSCs
following 24 hr incubation with apot MDA or apot
MDA pretreated with RNase (R) or DNase (D).
Values are means ± SD for triplicates of the assay.
(H) Real-time RT-PCR for TRAIL in hMSCs
following 24 hr treatment with poly (I:C). Values are
means ± SD for triplicates of the assay.
(I) Cell death assay in MDA by labeling with
Annexin V & 7AAD following 24 hr coculture with
poly (I:C)/TNF-a preactivated hMSCs and TNF-a.
Values are means ± SD (n = 3; **p < 0.01; two-
tailed Student’s t test).
(J) Number of live MDA cells following 24 hr
coculture with activated hMSCs andmouse IgG or
TLR3 blocking antibody (5 mg/ml). Values are
means ± SD (n = 3; **p < 0.01; two-tailed Student’s
t test).
See also Figure S4.
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decreased by exogenous rhDKK3 administration (Figures 6F,
S6A, 6G, and S6B) without affecting the viability of MDA cells
(Figure 6H). As expected, decreasing expression of DKK3 in
hMSCs with siRNA (Figure S6C) increased the recovery of
live MDA cells from cocultures (Figure 6I) and the number of
b-catenin-positive cells (Figure 6J). siRNA knockdown of DKK3
had no effect on apoptosis in the coculture system (Figure S6D),
indicating that expression of DKK3 did not inhibit or promote
TRAIL-induced apoptosis. Therefore, these data suggested
that hMSC activated with TNF-a inhibited cell-cycle progression
in MDA cells by secreting DKK3.
DISCUSSION
The results obtained here demonstrated that hMSCs incubated
with TNF-a expressed high levels of membrane-bound TRAIL830 Cell Stem Cell 11, 825–835, December 7, 2012 ª2012 Elsevier Inc.and hMSCs preactivated in culture to
express TRAIL reduced the tumor burden
in a xenograft mouse model of human
breast cancer lung metastases. The
results suggested therefore that appro-
priately preactivated hMSCsmay providea useful therapeutic strategy for cancers. The majority of
research involving hMSCs andmetastatic cancers has been per-
formed in lung metastasis models, because intravenously
infused cells are likely to be entrapped in the lungs (Lee et al.,
2009b). Therefore, the potential applications of the therapy
may be limited to cancers of the lung. However, there are
some indications that intravenously delivered hMSCs are able
to incorporate into tumors outside of the lung (Ling et al., 2010)
and that MSC homing is increased after radiation therapy (Klopp
et al., 2007). Whether intravenously infused activated MSCs are
able to accumulate in sufficient numbers in tumors outside of the
lung to slow their growth is yet to be determined. Direct injection
into tumors or intracardiac or arterial infusion may be more
efficient.
In contrast to hMSCs, human fibroblasts failed to induce
TRAIL-dependent apoptosis of MDA cells. In addition, the
apoptosis of MDA cells appeared to increase with time in culture,
Figure 5. hMSCs Activated with TNF-a Inhibited Cell-Cycle Progres-
sion in MDA Cells
(A) Cell cycle was assayed in adherent viable MDA cells following 24 hr
coculture with hMSCs or preactivated hMSCs.
(B) Western blot analyses for cyclin D1 and cyclin D3 levels in MDA cells
following 24 hr incubation with TNF-a or coculture with preactivated hMSCs.
(C–F) MDA cells were cultured with TNF-a or coculture with GFP-labeled
activated hMSCs for 24 hr.
(C) IF staining for cyclin D1 (Red) and GFP (green).
(D) Quantification of data of cyclin D1-expressing MDA cells from experiment
in (C). Values are means ± SD for three random fields with at least 50 cells per
field scored for each sample (n = 3; *p < 0.05; **p < 0.01; N.S., not significant;
one-way ANOVA).
(E) IF staining for p21 (Red) and GFP (green) from experiment in (C).
(F) Quantification of data of p21 expression inMDA cells from experiment in (E).
Values are means ± SD for three random fields with at least 50 cells per field
scored for each sample (n = 3; *p < 0.05; **p < 0.01; N.S., not significant; one-
way ANOVA).
See also Figure S5.
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Preactivated hMSCs Exert Tumor-Suppressive Effectsan observation largely explained by a further increase in expres-
sion of TRAIL by hMSCs in coculture. Most interestingly, the
enhanced expression of TRAIL in hMSCs observed in cocultures
with MDA cells was mediated by feedforward reaction that was
in part accounted for by RNA released from apoptotic MDA cells
interacting with TLR3 to increase NF-kB signaling and therebyCellactivate a pathway for upregulation of TRAIL (Rivera-Walsh
et al., 2001). In addition, DNA from the apoptotic MDA cells
may increase interactions of additional damage-associated
molecular patterns (DAMPs) with hMSCs through different
TLRs (Chen and Nun˜ez, 2010) and enhance TRAIL expression,
since treatment of the apoptotic MDA cells with DNase
decreased their effectiveness in enhancing TRAIL expression
in hMSCs. A recent study showed that microparticles released
by tumor cells undergoing in vitro apoptosis contained both
DNA and RNA, which can trigger responses via the Toll-like
receptors (Reich and Pisetsky, 2009). This observation may
help explain the results that we obtained in the coculture system.
Also, although apoptotic cells are effectively engulfed by neigh-
boring cells before releasing their intracellular content in vivo,
a recent report indicated that macrophages often fail to engulf
apoptotic cells until long after they have acquired the morpho-
logical hallmarks of apoptosis (Devitt et al., 2003). Therefore,
the feedforward reaction that increased expression of both
TRAIL and TLR3 may have increased the effectiveness of the
hMSCs in suppressing tumor progression in the mice even
though the cells engrafted in the tumors for only a short period
of time.
The results demonstrated that combination of hMSCs and
a low concentration of doxorubicin, a chemotherapy drug
commonly used for breast cancer, created a synergistic effect
on apoptosis of MDA cells. Indeed, it was previously shown
that doxorubicin synergistically enhances soluble recombinant
protein TRAIL-mediated apoptosis by activating caspase or
TRAIL receptors on cancer cells (Buchsbaum et al., 2003; Keane
et al., 1999; Singh et al., 2003). However, the combination also
increased toxicity in normal mammary epithelial cells (Keane
et al., 1999). In contrast, our data showed that a low dose of
doxorubicin combined with hMSCs was enough to induce
synergistic effects on apoptosis in MDA cells, suggesting that
this combination may be an effective therapy.
We also observed that hMSCs from different preparations
varied in their activation of TRAIL and efficacy in inducing
apoptosis in MDA cells. The variations may reflect sampling
problems in obtaining hMSCs with bone marrow aspirates or
intrinsic differences in hMSCs from different donors (Phinney
et al., 1999). In addition, the same preparations became less
effective after they were extensively expanded in culture.
Therefore, our observationsmay help to explain some of the con-
flicting results previously reported in the literature because rela-
tively little attention was paid to the differences between rodent
and humanMSCs, the quality of MSC preparations, and the con-
ditions for expanding them in culture (Prockop et al., 2010). Also,
some of the conflicting results may be explained by the experi-
ments being conducted with both TRAIL-sensitive and TRAIL-
insensitive cancer cell lines.
In addition, it has been shown that IFN-a and IFN-b have
antitumor effects against some cancers (Ida et al., 1982) by
inducing higher levels of TRAIL in immune cells, which displayed
apoptotic activity on cancer cells (Arbour et al., 2005; Borden
et al., 2011; Tecchio et al., 2004). Interestingly, it has been
recently shown that IFN-b treatment increased TRAIL in serum
of patients with metastatic melanoma and the patient who had
the sustained tumor regression showed the highest level of
TRAIL (Borden et al., 2011). Therefore, we speculate that theStem Cell 11, 825–835, December 7, 2012 ª2012 Elsevier Inc. 831
Figure 6. DKK-3 Expressed by Activated
hMSCs in Cocultures Decreased Prolifera-
tion on MDA Cells
(A–D) MDA cells were cultured with TNF-a or
coculture with GFP-labeled activated hMSCs for
24 hr. (A) Real-time RT-PCR for DKK3. Values are
means ± SD for triplicates of the assay. (B)
Western blots for DKK3. (C) ELISA assay for DKK3
in medium. Values are means ± SD (n = 3; **p <
0.01; N.S. – Not significant; one-way ANOVA). (D)
IF staining for b-catenin (Red) and GFP (green).
(E) Quantification of data of b-catenin-expressing
MDA cells from experiment in (D). Values are
means ± SD for three random fields with at least 50
cells per field scored for each sample (n = 3; **p <
0.01; N.S., not significant; one-way ANOVA).
(F) Quantification of b-catenin-expressing MDA
cells following 24 hr incubation with rhDKK3 (R&D
Systems) in 2% CM. Values are means ± SD for
five random fields with at least 50 cells per field
scored for each sample (n = 5; **p < 0.01; one-way
ANOVA).
(G) MTT assay showing the rate of cell proliferation
of MDA cells following 24 hr incubation with
rhDKK3. Values are means ± SD (n = 9; **p < 0.01;
one-way ANOVA).
(H) Cell death assay in MDA cells following 24 hr
treatment with rhDKK3 (5 ng/ml) by labeling with
Annexin V & 7AAD.
(I) Number of live MDA cells following 24 hr
coculture with activated hMSCs transduced with
scr siRNA (control) or DKK3 siRNA. Values are
means ± SD (n = 3; *p < 0.05; two-tailed Student’s t
test).
(J) Quantification of b-catenin-expressing MDA
cells from the experiment as in (I). Values are
means ± SD for five random fields with at least 50
cells per field scored for each sample (n = 5; **p <
0.01; one-way ANOVA).
See also Figure S6.
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Preactivated hMSCs Exert Tumor-Suppressive Effectsvariations in TRAIL expression in not only MSCs, but also
cancer-associated stromal cells or immune cells, may also
reflect different susceptibilities to cancer metastases. TRAIL is
generally accepted as not affecting noncancer cells and few
nonspecific side effects have been reported with administration
of MSCs. However, the results presented here do not rule out the
possibility that MSCs activated to express TRAIL may have
nonspecific side effects such as increasing the expression of
nononcogenes that may enhance the cancer cell growth (Luo
et al., 2009).
Furthermore, we demonstrated that DKK3 expressed by
hMSCs inhibited cell-cycle progression in MDA cells. This
suppressive effect was enhanced by preactivated hMSCs and
reduced by a siRNA knockdown of DKK3 (Figure 6I). In the
coculture system, there was a decrease in b-catenin and cell-
cycle proteins. These data suggested that DKK3 expressed
by hMSCs decreased cell-cycle progression of MDA cells832 Cell Stem Cell 11, 825–835, December 7, 2012 ª2012 Elsevier Inc.by suppressing Wnt/b-catenin-mediated
signaling. Recently, inhibiting b-catenin
signaling has been suggested as a poten-
tial treatment for cancer. Indeed, benefi-cial effects in colorectal cancer were observed by disrupting
Wnt/b-catenin signaling with nonsteroidal anti-inflammatory
drugs (Castellone et al., 2005; Shao et al., 2005) or with natural
antagonists of theWnt pathway such as secreted frizzled-related
proteins (Suzuki et al., 2004), DKK (Gonza´lez-Sancho et al.,
2005), or small molecules (Lepourcelet et al., 2004). Also,
evidence is accumulating that the secreted Wnt antagonist
DKK3 and its regulators may constitute effective therapeutic
targets for most human cancers (Veeck and Dahl, 2012). Ectopic
DKK-3 expression prevented nuclear accumulation of b-catenin
and decreased the expression of the Wnt target genes c-Myc
and cyclin-D1 in non-small cell lung cancer cell lines (Yue
et al., 2008). The results here add evidence that exogenous
DKK3 can inhibit Wnt/b-catenin-mediated cell proliferation of
cancer cells.
In summary, our data suggest that hMSCs activated to
express TRAIL may have several advantages as therapy for
Cell Stem Cell
Preactivated hMSCs Exert Tumor-Suppressive Effectssome cancers: (1) they avoid the complexities and dangers
encountered by viral transfection with the TRAIL gene; (2) they
deliver the potent membrane-tethered form of TRAIL and
tumor-suppressive protein DKK3 in high local concentrations
to cancers; and (3) they may provide a therapy for metastatic




hMSCs were prepared as previously described (Lee et al., 2009b). MDA-
MB-231, MDA-MB-436, HeLa, HCC38, A549, CFPAC, U87, Hs68, and two
different human dermal fibroblasts were purchased from ATCC (Manassa,
VA) and GIBCO (Grand Island, NY).
Animals
Six-week-old male NOD/SCID mice (NOD.CB17-Prkdcscid/J) from the
Jackson Laboratory (Bar Harbor, ME) were used under a protocol approved
by the Institutional Animal Care and Use Committee of Texas A&M Health
Science Center College of Medicine.
Lung Xenograft Model, hMSC Infusion, and Tissue Collection
Animals were injected through a tail vein with 2 3 106 MDA cells in order to
initiate lung metastases. Beginning one week later, mice were injected
weekly intravenously with HBSS, 2 3 106 hMSCs, or preactivated hMSCs for
a total of four or nine injections, a protocol similar to that used previously (Loe-
binger et al., 2009). Preactivated hMSCswere prepared by incubating the cells
for 24 hr before injectionwith recombinant human TNF-aprotein (TNF-a; 10 ng/
ml; R&D Systems; Minneapolis, MN) in 2% culture medium (2% CM; a-MEM
containing 2% fetal bovine serum [FBS; lot-selected for rapid growth of
MSCs; Atlanta Biologicals, Inc, Norcross, GA], 100 units/ml penicillin,
100 mg/ml streptomycin, and 2 mM L-glutamine [Invitrogen, Grand Island,
NY]). For injection, hMSCs were harvested with 0.25% trypsin/1 mM EDTA
and resuspended at 2 3 106 cells in 200 ml of HBSS. One week after the last
injection, lungs were collected for assay (see Supplemental Information).
Cocultures of Human MSCs and MDA Cells
hMSCs were plated at 105 cells in CCM (a-MEM containing 17% FBS,
100 units/ml pen/strep, and 2 mM L-glutamine) in 6-well plates and incubated
for 4 hr. For preactivation, hMSCs were incubated at 37C for 24 hr in 2% CM
containing 10 ng/ml TNF-a. For coculture, an equal number of MDA cells in 2%
CM with or without TNF-a (10 ng/ml) were added to hMSC-containing wells.
For transwell cultures, hMSCs were plated at 105 cells in the upper compart-
ment (Transwell, 0.4 mm pore size; Corning; Corning, NY), while an equal
number of MDA cells was plated in the lower compartment in 2% CM with
or without TNF-a (10 ng/ml). After 24 hr, supernatants and cells were collected.
For some experiments, MDA cells were treated with 1 to 100 ng/ml doxoru-
bicin (Sigma-Aldrich) in 2% CM for 24 hr at 37C, prior to coculture with
hMSCs. In other experiments, hMSCs were treated with either apoptotic
MDA cells or 1 mg/ml Polyinosinic-Polycytidylic acid [Poly(I:C); Sigma-Aldrich;
St. Louis, MO] with or without TNF-a (10 ng/ml) for 24 hr in 2% CM.
Preparation of Apoptotic MDA Cells
MDA cells were plated in serum-free a-MEM with 100 ng/ml rhTRAIL (R&D
Systems). After 24 hr at 37C, floating cells were collected and washed by
centrifugation at 500 3 g for 5 min. The pellet was resuspended in 2% CM
and plated on hMSC-containing wells. For RNase and DNase treatment,
apoptotic MDA cells were washed by centrifugation, resuspended in 0.2 ml
PBS containing either 20 mg of RNase (QIAGEN, Valencia, CA) or 30 units of
DNase (QIAGEN), and incubated for 2 hr at 37C. The cells were washed
by centrifugation and resuspended in 2% CM before being added to hMSC-
containing wells.
Flow Cytometry
hMSCs and MDA cells from coculture experiments were suspended in PBS
and incubated with CD90-PE (Clone Thy1/310; Beckman Coulter) for 45 minCellon ice, washed with PBS by centrifugation, incubated at RT for 20 min with
300 ng/ml annexin V (AnnexinV-FITC Apoptosis Detection Kit; Sigma-Aldrich)
and 4 mg/ml 7-aminoactinomycin D (7AAD; Sigma-Aldrich.), and analyzed by
flow cytometry (Cytomics FC500; Beckman Coulter).
RNA Extraction from Cultured Cells and Real-Time RT-PCR Analysis
hMSCs and MDA cells were separated by cell sorting (FACS, MoFlo XDP;
Beckman Coulter; Brea, CA) after labeling with CD90-PE for 45 min on ice.
RNA was extracted using RNeasy Mini Kit (QIAGEN). See Supplemental Infor-
mation for real time RT-PCR analysis.
Cell-Cycle Analysis
Both hMSCs and MDA cells were cocultured for 24 hr at 37C. Conditioned
media and apoptotic cells were aspirated and adherent cells were lifted using
0.25% trypsin/1 mM EDTA followed by resuspension in ice-cold 75% ethanol
for fixation for 1 hr on ice. The fixed cells were washed with PBS followed by
centrifugation and incubated overnight at 4C with 10 mg/ml propidium iodide
(P.I.; Sigma-Aldrich) before flow cytometry.
Transfections with siRNA
hMSCs (53 104 cells/well in 6-well plates) were transfected by incubating 6 hr
with 20 nM siRNA for DKK3 Trilencer-27 (Origene Technologies, Inc., Rock-
ville, MD) or Universal Scrambled Negative Control siRNA Duplex (Origene)
using Lipofectamine RNAiMax reagent (Invitrogen).
Antibody Blocking Assay
hMSCs (53 104 cells/well in 6-well plates) were treated with either TLR3 anti-
body (5 mg/ml; eBioscience, Inc; San Diego, CA), TRAIL antibody (25 mg/ml; BD
Biosciences, Inc; San Jose, CA), or normal mouse IgG (5 or 25 mg/ml; Pepro-
Tech, Inc; Rocky Hill, NJ) for 30 min at 37C in 2% CM with or without TNF-a
(10 ng/ml) prior to coculture with an equal number of MDA cells for 24 hr.
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